Efficacy of methylprednisolone in children with severe community acquired pneumonia

Bela Nagy, Imre Gaspar, Agnes Papp, Zsolt Bene, Z. Vokó, G. Balla

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background The clinical value of adjuvant corticosteroid treatment in community-acquired pneumonia (CAP) seemed to be controversial in adults, and even less data are available on the use of corticosteroids in children with CAP. Materials and Methods In this study, we investigated the efficacy of a 5-day adjuvant methylprednisolone therapy to imipenem in 29 children with severe CAP. In parallel, 30 subjects with the same disease were treated with imipenem and placebo, and the two study groups were compared based on the different parameters of the primary and secondary end points. The primary end points were the duration of fever, the levels of white blood cells (WBC) and high sensitive C-reactive protein (hsCRP). Secondary end points were the length of hospital stay, and the number of severe complications with or without surgical interventions. Results The additive methylprednisolone treatment significantly reduced the duration of fever with 2.5 days, the WBC counts (P = 0.014), the hsCRP levels showing a 48.7% decrease, and the length of hospital stay with 5.2 days versus the placebo group. Moreover, patients treated on imipenem alone had twice more complications and four times more invasive interventions compared to those on the combined therapy. Conclusions The 5-day methylprednisolone therapy with imipenem was found effective in children having severe CAP. However, trials with larger cohorts are needed to study further beneficial effects of corticosteroids in children with CAP. Pediatr Pulmonol. 2013; 48:168-175. © 2012 Wiley Periodicals, Inc.

Original languageEnglish
Pages (from-to)168-175
Number of pages8
JournalPediatric Pulmonology
Volume48
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Methylprednisolone
Imipenem
Pneumonia
Length of Stay
Adrenal Cortex Hormones
C-Reactive Protein
Fever
Placebos
Therapeutics
Leukocyte Count
Leukocytes

Keywords

  • childhood
  • community acquired pneumonia
  • corticosteroid
  • imipenem

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Efficacy of methylprednisolone in children with severe community acquired pneumonia. / Nagy, Bela; Gaspar, Imre; Papp, Agnes; Bene, Zsolt; Vokó, Z.; Balla, G.

In: Pediatric Pulmonology, Vol. 48, No. 2, 02.2013, p. 168-175.

Research output: Contribution to journalArticle

Nagy, Bela ; Gaspar, Imre ; Papp, Agnes ; Bene, Zsolt ; Vokó, Z. ; Balla, G. / Efficacy of methylprednisolone in children with severe community acquired pneumonia. In: Pediatric Pulmonology. 2013 ; Vol. 48, No. 2. pp. 168-175.
@article{be03fadb2dc341fc9a92e2711b097b1e,
title = "Efficacy of methylprednisolone in children with severe community acquired pneumonia",
abstract = "Background The clinical value of adjuvant corticosteroid treatment in community-acquired pneumonia (CAP) seemed to be controversial in adults, and even less data are available on the use of corticosteroids in children with CAP. Materials and Methods In this study, we investigated the efficacy of a 5-day adjuvant methylprednisolone therapy to imipenem in 29 children with severe CAP. In parallel, 30 subjects with the same disease were treated with imipenem and placebo, and the two study groups were compared based on the different parameters of the primary and secondary end points. The primary end points were the duration of fever, the levels of white blood cells (WBC) and high sensitive C-reactive protein (hsCRP). Secondary end points were the length of hospital stay, and the number of severe complications with or without surgical interventions. Results The additive methylprednisolone treatment significantly reduced the duration of fever with 2.5 days, the WBC counts (P = 0.014), the hsCRP levels showing a 48.7{\%} decrease, and the length of hospital stay with 5.2 days versus the placebo group. Moreover, patients treated on imipenem alone had twice more complications and four times more invasive interventions compared to those on the combined therapy. Conclusions The 5-day methylprednisolone therapy with imipenem was found effective in children having severe CAP. However, trials with larger cohorts are needed to study further beneficial effects of corticosteroids in children with CAP. Pediatr Pulmonol. 2013; 48:168-175. {\circledC} 2012 Wiley Periodicals, Inc.",
keywords = "childhood, community acquired pneumonia, corticosteroid, imipenem",
author = "Bela Nagy and Imre Gaspar and Agnes Papp and Zsolt Bene and Z. Vok{\'o} and G. Balla",
year = "2013",
month = "2",
doi = "10.1002/ppul.22574",
language = "English",
volume = "48",
pages = "168--175",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Efficacy of methylprednisolone in children with severe community acquired pneumonia

AU - Nagy, Bela

AU - Gaspar, Imre

AU - Papp, Agnes

AU - Bene, Zsolt

AU - Vokó, Z.

AU - Balla, G.

PY - 2013/2

Y1 - 2013/2

N2 - Background The clinical value of adjuvant corticosteroid treatment in community-acquired pneumonia (CAP) seemed to be controversial in adults, and even less data are available on the use of corticosteroids in children with CAP. Materials and Methods In this study, we investigated the efficacy of a 5-day adjuvant methylprednisolone therapy to imipenem in 29 children with severe CAP. In parallel, 30 subjects with the same disease were treated with imipenem and placebo, and the two study groups were compared based on the different parameters of the primary and secondary end points. The primary end points were the duration of fever, the levels of white blood cells (WBC) and high sensitive C-reactive protein (hsCRP). Secondary end points were the length of hospital stay, and the number of severe complications with or without surgical interventions. Results The additive methylprednisolone treatment significantly reduced the duration of fever with 2.5 days, the WBC counts (P = 0.014), the hsCRP levels showing a 48.7% decrease, and the length of hospital stay with 5.2 days versus the placebo group. Moreover, patients treated on imipenem alone had twice more complications and four times more invasive interventions compared to those on the combined therapy. Conclusions The 5-day methylprednisolone therapy with imipenem was found effective in children having severe CAP. However, trials with larger cohorts are needed to study further beneficial effects of corticosteroids in children with CAP. Pediatr Pulmonol. 2013; 48:168-175. © 2012 Wiley Periodicals, Inc.

AB - Background The clinical value of adjuvant corticosteroid treatment in community-acquired pneumonia (CAP) seemed to be controversial in adults, and even less data are available on the use of corticosteroids in children with CAP. Materials and Methods In this study, we investigated the efficacy of a 5-day adjuvant methylprednisolone therapy to imipenem in 29 children with severe CAP. In parallel, 30 subjects with the same disease were treated with imipenem and placebo, and the two study groups were compared based on the different parameters of the primary and secondary end points. The primary end points were the duration of fever, the levels of white blood cells (WBC) and high sensitive C-reactive protein (hsCRP). Secondary end points were the length of hospital stay, and the number of severe complications with or without surgical interventions. Results The additive methylprednisolone treatment significantly reduced the duration of fever with 2.5 days, the WBC counts (P = 0.014), the hsCRP levels showing a 48.7% decrease, and the length of hospital stay with 5.2 days versus the placebo group. Moreover, patients treated on imipenem alone had twice more complications and four times more invasive interventions compared to those on the combined therapy. Conclusions The 5-day methylprednisolone therapy with imipenem was found effective in children having severe CAP. However, trials with larger cohorts are needed to study further beneficial effects of corticosteroids in children with CAP. Pediatr Pulmonol. 2013; 48:168-175. © 2012 Wiley Periodicals, Inc.

KW - childhood

KW - community acquired pneumonia

KW - corticosteroid

KW - imipenem

UR - http://www.scopus.com/inward/record.url?scp=84872414822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872414822&partnerID=8YFLogxK

U2 - 10.1002/ppul.22574

DO - 10.1002/ppul.22574

M3 - Article

VL - 48

SP - 168

EP - 175

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 2

ER -